Has Randy Smargiassi, DPM received payments from drug or device companies?

Yes. Drug and device makers reported $1,288 in general payments to Randy Smargiassi, DPM across 62 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Randy Smargiassi, DPM did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Randy Smargiassi, DPM come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Randy Smargiassi, DPM

Podiatrist · Reading, PANPI 1407828825

Payments from drug & device makers

$1,288in general payments, 2019–2025

Across 62 payments — averaging $20.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Paratek Pharmaceuticals, Inc.$271
Novus Surgical Consultants$139
Nevro Corp.$125
AbbVie$90
Treace Medical Concepts, Inc.$76
Musculoskeletal Transplant Foundation Inc.$74
plus $514 from 16 others

What the payments were for

Food & beverage$1,21494%
Entertainment$746%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Paratek Pharmaceuticals, Inc.	16	$271
Novus Surgical Consultants	1	$139
Nevro Corp.	6	$125
AbbVie	5	$90
Treace Medical Concepts, Inc.	2	$76
Musculoskeletal Transplant Foundation Inc.	2	$74
Smith+Nephew	3	$70
Organogenesis Inc.	4	$59
KCI USA, Inc.	3	$56
AstraZeneca	3	$52
Zyla Life Sciences, Inc.	3	$46
Paragon 28, Inc.	2	$42
Kerecis Limited	2	$31
Aroa Biosurgery Incorporated	1	$23
Merck	2	$23
Bioventus LLC	1	$19
Kowa Pharmaceuticals America, Inc.	1	$17
Nabriva Therapeutics, PLC	1	$17
ERMI LLC	1	$16
Urgo Medical North America, LLC	1	$16
Stryker	1	$14
Medtronic	1	$14

How this compares

$1,288 in reported general payments places this provider in the 65th percentile of 445 podiatrist providers in Pennsylvania.

See all podiatrist providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$83,893

Medicare patients

198

Services billed

765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ammonium Lactate	107	$1,907
Terbinafine Hcl	79	$1,705
Gabapentin	28	$368
Methylprednisolone	37	$313
Sulindac	18	$248
Doxycycline Hyclate	11	$166
Levofloxacin	14	$138
Mupirocin	19	$134
Meloxicam	34	$114

Paid to pharmacies, not to this prescriber.

Payments from drug & device makers

Who reported the general payments

How this compares

Medicare billing

Most prescribed under Part D

Other podiatrist in Reading